Plus Therapeutics signs Medical Mutual coverage deal for CNSide CSF tumor cell assay in Ohio, KentuckyPUBT·Jul 21 at 06:30 AMPSTV-3.46%
Plus Therapeutics partners with Genomic Testing Cooperative to add NGS to CNSide CSF assay platformPUBT·Jul 16 at 06:31 AMPSTV-3.46%
From Buybacks to Insider Buying: U.S. Mid-Caps Signal Capital ShiftGlobal Report·Jul 14 at 06:47 AMBDX+1.24%AB-0.64%
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases MonitoringUnusual Whales·Jul 14 at 06:31 AMPSTV-3.46%
Plus Therapeutics flags availability of CNS cancers guidelines update releasePUBT·Jul 14 at 06:31 AMPSTV-3.46%
PSTV: Cerenome advances CNS oncology with integrated therapeutics, diagnostics, and native AIQuartr·Jun 30 at 09:40 AMPSTV-3.46%
Plus Therapeutics reaffirms 2026 milestones guidance for CNSide diagnostics businessPUBT·Jun 30 at 06:35 AMPSTV-3.46%
Plus Therapeutics rebrands as Cerenome, to trade as CNSY on Nasdaq from Aug. 3, 2026PUBT·Jun 30 at 06:31 AMPSTV-3.46%
Plus Therapeutics unit CNSide signs national coverage deal with Elevance Health for CSF cancer assayPUBT·Jun 25 at 06:30 AMPSTV-3.46%ELV-2.53%
